Market Overview

Sucampo, Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation


Sucampo Pharmaceuticals (Nasdaq: SCMP) and its development and commercialization partner Takeda Pharmaceuticals (OTC: TKPYY) today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the rise. An analysis of longitudinal data in the United States showed a nearly 4-fold increase in rates of constipation over the last decade.1

See full press release

Posted-In: News Guidance Contracts Asset Sales FDA Management Global


Related Articles (SCMP + TKPYY)

View Comments and Join the Discussion!